Pedro Lopez-Romero

5PUBLICATIONS
18CO-AUTHORS
Epidemiological modellingClinical pharmacology and therapeuticsPredictive and prognostic markersBiomechanics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 06, 2026
Applying the estimand framework to safety: aligning estimators with treatment effects in the presence of intercurrent events.

|Feb 23, 2022
Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.

Pedro Lopez-Romero, Inmaculada de la Torre, Ewa Haladyj

|Aug 20, 2020
Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN.

Pedro López-Romero, Lorena Martinez-Gamboa, Holger Bang

|Jun 01, 2020
Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial.

J-J Body, F Marin, D L Kendler

|Mar 12, 2020
Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial.

Piet Geusens, David L Kendler, Astrid Fahrleitner-Pammer

Pageof 1

Frequent Collaborators

2 joint publications

Fernando Marin

2 joint publications

Astrid Fahrleitner-Pammer

2 joint publications

Piet Geusens

1 joint publications

J-J Body